Psychology Wiki

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)

Chemical name Bromo-benzodifuranyl-isopropylamine or
Chemical formula C13H12BrNO2
Molecular mass 294.14 g/mol
Melting point decomposes at 240 °C (hydrochloride)
CAS number -
C(Br)C3=C1C=CO3 (R-isomer)
chemical structure of (R)-Bromo-DragonFLY

Bromo-DragonFLY, also known as ABDF, is a psychedelic hallucinogenic drug somewhat related to the phenethylamine family. Bromo-DragonFLY is considered an extremely potent hallucinogen, only slightly less potent than LSD with a normal dose in the region of 200μg to 800μg, and it has an extremely long duration of action. It is not illegal anywhere in the world at this time although it may be considered a controlled substance analogue under US and Australian drug laws. Bromo-DragonFLY has a stereocenter and R-(-)-bromo-DragonFLY is the more active stereoisomer.


The hallucinogenic effect of bromo-DragonFLY is mediated by its full agonistic activity at the 5-HT2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptor. It can sometimes be found on "blotters" (small bits of paper containing the substance) reminiscent of the most commonly found form of LSD, thus making it difficult to identify which substance it is carrying.


Bromo-DragonFLY was first synthesized by Matthew A. Parker in the laboratory of David E. Nichols in 1998.

See also


  • 'A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor' by M. A. Parker, D. Marona-Lewicka, V. L. Lucaites, D. L. Nelson, and D. E. Nichols in J. Med. Chem. 41(26): 5148-5149 (1998) DOI: 10.1021/jm9803525
  • 'Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists' by J. J. Chambers, D. M. Kurrasch-Orbaugh, M. A. Parker, and D. E. Nichols in J. Med. Chem. 44(6): 1003-1010 (2001) DOI: 10.1021/jm000491y

External links


This page uses Creative Commons Licensed content from Wikipedia (view authors).